Found 411 results
Micci L, Cervasi B, Ende ZS, Iriele RI, Reyes-Aviles E, Vinton C, Else JG, Silvestri G, Ansari AA, Villinger F et al..  2012.  Paucity of interleukin (IL-21)-producing CD4+ T-cells is associated with Th17 cell depletion in SIV-infection of rhesus macaques.. Blood.
Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, Amara R R.  2012.  PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques.. J Clin Invest. 122(5):1712-6.
Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD et al..  2012.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.. J Virol. 86(8):4394-403.
Mouquet H, Nussenzweig MC.  2012.  Polyreactive antibodies in adaptive immune responses to viruses.. Cell Mol Life Sci. 69(9):1435-45.
Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH.  2012.  Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.. J Infect Dis. 205(12):1806-10.
Angin M, Kwon DS, Streeck H, Wen F, King M, Rezai A, Law KM, Hongo TC, Pyo A, Piechocka-Trocha A et al..  2012.  Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue.. J Infect Dis. 205(10):1495-500.
Mackelprang RD, Baeten JM, Donnell D, Celum C, Farquhar C, de Bruyn G, Essex M, McElrath JM, Nakku-Joloba E, Lingappa JR.  2012.  Quantifying Ongoing HIV-1 Exposure in HIV-1-Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1.. J Infect Dis. 206(8):1299-1308.
Porichis F, Kaufmann DE.  2012.  Role of PD-1 in HIV pathogenesis and as target for therapy.. Curr HIV/AIDS Rep. 9(1):81-90.
Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose NA, Hoxie JA, Connors M et al..  2012.  Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.. J Virol. 86(10):5844-56.
Doria-Rose NA, Georgiev I, O'Dell S, Chuang G-Y, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF et al..  2012.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.. J Virol. 86(15):8319-23.
Mir KD, Bosinger SE, Gasper M, Ho O, Else JG, Brenchley JM, Kelvin DJ, Silvestri G, Hu S-L, Sodora DL.  2012.  Simian immunodeficiency virus-induced alterations in monocyte production of tumor necrosis factor alpha contribute to reduced immune activation in sooty mangabeys.. J Virol. 86(14):7605-15.
West AP, Diskin R, Nussenzweig MC, Bjorkman PJ.  2012.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.. Proc Natl Acad Sci U S A. 109(30):E2083-90.
Guenaga J, Wyatt RT.  2012.  Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.. PLoS Pathog. 8(7):e1002806.
Sekaly R-P, Pulendran B.  2012.  Systems biology in understanding HIV pathogenesis and guiding vaccine development.. Curr Opin HIV AIDS. 7(1):1-3.
Nakaya HI, Pulendran B.  2012.  Systems vaccinology: its promise and challenge for HIV vaccine development.. Curr Opin HIV AIDS. 7(1):24-31.
Walker BD, McMichael A.  2012.  The T-Cell Response to HIV.. Cold Spring Harb Perspect Med.
Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A et al..  2012.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.. Nat Immunol. 13(7):691-700.
Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun T-W, Churchill M, Di Mascio M, Katlama C et al..  2012.  Towards an HIV cure: a global scientific strategy.. Nat Rev Immunol. 12(8):607-14.
Vanderford TH, Slichter C, Rogers KA, Lawson BO, Obaede R, Else JG, Villinger F, Bosinger SE, Silvestri G.  2012.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.. Blood. 119(24):5750-7.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro JM, Sanmiguel A, Seaman MS, Ferrari G et al..  2012.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.. Nature. 482(7383):89-93.
Doehle BP, Chang K, Rustagi A, McNevin J, McElrath JM, Gale M.  2012.  Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism.. J Virol. 86(16):8367-74.
Doehle BP, Chang K, Fleming L, McNevin J, Hladik F, McElrath JM, Gale M.  2012.  Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells.. J Virol. 86(16):8499-506.